Optimer Pharmaceuticals Inc. has earned analyst and investor kudos for its successful launch of Dificid (fidaxomicin). The macrolide antibiotic for Clostridium difficile Infection (CDI) had fourth quarter 2011 net sales of about $11 million and has bucked the biotech trend of underperforming analyst launch estimates.